Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytotoxic etherphospholipid analogues

D Berkovic1

  • 1Department of Hematology and Oncology, The University Clinic of Göttingen, Germany.

General Pharmacology
|October 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Endoscopic removal of an intraluminal duodenal diverticulum in an adult with upper abdominal pain].

Zeitschrift fur Gastroenterologie·2004
Same author

[Posthepatic icterus caused by a solitary granular cell tumor of the common bile duct].

Zeitschrift fur Gastroenterologie·2004
Same author

Carcinoma of the pancreas with neuroendocrine differentiation and nodular panniculitis.

Onkologie·2003
Same author

Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?

Annals of hematology·2003
Same author

Effects of hexadecylphosphocholine on thrombocytopoiesis.

European journal of cancer (Oxford, England : 1990)·2001
Same author

Expression of two 50 kDa proteins is associated with sensitivity towards etherlipid analogues in the human leukaemia cell line HL 60.

European journal of cancer (Oxford, England : 1990)·1998

Alkyllysophospholipids demonstrate potent anti-cancer effects against tumor cells. These etherphospholipid analogues show promise in cancer therapy by interfering with crucial intracellular signal transduction pathways.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Alkyllysophospholipids, derived from cell membrane phospholipids, exhibit significant cytostatic and cytotoxic activity against various malignant tumor cell lines and tumors.
  • Etherphospholipid analogues possess diverse biological properties, including the induction of cellular maturation, inhibition of tumor cell invasion, and modulation of immune responses, indicating their therapeutic potential in oncology.
  • Hexadecylphosphocholine (HePC), an etherphospholipid analogue, is an approved drug for treating mammary carcinoma in Germany, highlighting the clinical relevance of this drug class.

Purpose of the Study:

  • To investigate the underlying mechanisms of action for etherphospholipid analogues in cancer therapy.
  • To explore the role of intracellular signal transduction in the biological effects of etherphospholipid analogues.

Related Experiment Videos

Main Methods:

  • Extensive biochemical investigations were conducted to elucidate the mode of action.
  • Studies focused on the interference of etherphospholipid analogues with intracellular signal transduction pathways.

Main Results:

  • Etherphospholipid analogues exhibit broad-spectrum anticancer activity in vitro and in vivo.
  • Clinical trials have shown efficacy for certain etherphospholipid analogues, with HePC being commercially available for breast cancer treatment.
  • Growing evidence suggests that etherphospholipid analogues significantly interfere with intracellular signal transduction pathways, contributing to their therapeutic effects.

Conclusions:

  • Etherphospholipid analogues represent a promising class of anticancer agents with diverse therapeutic applications.
  • Further research into the precise mechanisms, particularly their interaction with signal transduction, is crucial for optimizing their use in cancer treatment.